amino-6 dimethyl-5,8 isoquinoleine | 24843-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: amino-6 dimethyl-5,8 isoquinoleine
• 英文别名: 6-Amino-5,8-dimethyl-isochinolin；6-amino-5,8-dimethylisoquinoline；5,8-dimethyl-isoquinolin-6-ylamine；5,8-dimethyl-6-amino-isoquinoline；5,8-dimethylisoquinolin-6-amine
• CAS: 24843-31-0
• 化学式: C₁₁H₁₂N₂
• 分子量: 172.23
• InChiKey: ISYOKIKEVPRGAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  amino-6 dimethyl-5,8 isoquinoleine 在 镍 一水合肼 、 sodium amide 作用下， 以 乙醇 、 苯 为溶剂， 反应 23.0h， 生成 (amino-2' methoxy-5'-anilino)-6 dimethyl-5,8 isoquinoleine
  参考文献：
  名称：

  Gansser; Migambanou; Viel, Farmaco, Edizione Scientifica, 1985, vol. 40, # 7, p. 459 - 476

  摘要：

  DOI：

文献信息

• NOVEL COMPOUNDS DERIVED FROM INDOLE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Lejeune Fabrice

  公开号：US20110003843A1

  公开（公告）日：2011-01-06

  The present invention relates to a compound derived from indole corresponding to the following formula II: wherein X represents N, CR8 or N + R8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or benzyl group; R5 represents a hydrogen atom or an optionally substituted, saturated or unsaturated alkyl group, amine, benzyl group; R6 represents an optionally substituted C1-C3 alkyl group; R7 represents a hydrogen atom or an optionally substituted C1-C3 alkyl group and R7 is absent when the ring A is in the b position, and A represents a ring; R9 and R10 represent together a carbon bond or independently represent an R11 OR11, SR11 group; wherein R11 represents a hydrogen atom, an optionally substituted, saturated or unsaturated, C1-C3 alkyl group, which may contain one or more sulfur, oxygen or nitrogen atoms; pharmaceutically acceptable salts of said compounds, their isomers and/or a mixture thereof; pharmaceutical composition comprising such a compound; the use of such a compound for preparing a drug intended to treat a genetic disease resulting from at least one mutation causing the occurrence of an early termination codon.

  本发明涉及一种从吲哚衍生的化合物，对应于以下公式II： 其中，X表示N，CR8或N+R8，其中R8表示氢原子，羟基或烷基或甲氧基，可选地取代为苯基；R2、R3和R4分别表示氢原子或卤素原子或可选地取代的烷基、胺基、烯烃、酯、磺酰胺、醚或苄基；R5表示氢原子或可选地取代的饱和或不饱和烷基、胺基、苄基；R6表示可选地取代的C1-C3烷基；R7表示氢原子或可选地取代的C1-C3烷基，当环A在b位置时，R7不存在；A表示一个环；R9和R10共同表示碳键，或分别表示R11 OR11、SR11基团；其中，R11表示氢原子、可选地取代的饱和或不饱和的C1-C3烷基，可以含有一个或多个硫、氧或氮原子；该化合物的药学可接受盐、其异构体和/或混合物；包括这种化合物的药物组合物；使用这种化合物制备用于治疗由至少一个突变引起的早期终止密码子出现的遗传疾病的药物。
• Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
  申请人：ABIVAX

  公开号：US10253020B2

  公开（公告）日：2019-04-09

  The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

  式（Ia）化合物或其药学上可接受的盐的制造和使用，用于预防、抑制或治疗癌症、艾滋病和/或早衰。式 (Ia)化合物为： 其中 R 独立地代表氢原子、卤素原子、(C1-C3)烷基、-CN 基团、羟基、-COOR1 基团、(C1-C3)氟烷基、-NO2 基团、-NR1R2 基团或(C1-C3)烷氧基； R′ 是氢原子、卤素原子、(C1-C3)烷基、- 基团、(C1-C3)烷氧基或 -NR1R2 基团；以及 R1 和 R2 是氢原子或 (C1-C3) 烷基。
• Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging
  申请人：ABIVAX

  公开号：US10683284B2

  公开（公告）日：2020-06-16

  The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

  式（Ia）化合物或其药学上可接受的盐的制造和使用，用于预防、抑制或治疗癌症、艾滋病和/或早衰。式 (Ia)化合物为： 其中 R 独立地代表氢原子、卤素原子、(C1-C3)烷基、-CN 基团、羟基、-COOR1 基团、(C1-C3)氟烷基、-NO2 基团、-NR1R2 基团或(C1-C3)烷氧基； R′ 是氢原子、卤素原子、(C1-C3)烷基、- 基团、(C1-C3)烷氧基或 -NR1R2 基团；以及 R1 和 R2 是氢原子或 (C1-C3) 烷基。
• Compound, and production method thereof, and methods of treatment using the compound
  申请人：ABIVAX

  公开号：US10975063B2

  公开（公告）日：2021-04-13

  The manufacture of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, and use of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, for treating various conditions, and/or inhibiting replication of HIV-1 in a patient infected with HIV-1, by administering to a patient in need thereof an effective quantity of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof.

  8-氯-N-[4-(三氟甲氧基)苯基]喹啉-2-胺或其药学上可接受的盐的制造，以及8-氯-N-[4-(三氟甲氧基)苯基]喹啉-2-胺或其药学上可接受的盐用于治疗各种疾病、和/或通过向有需要的患者施用有效量的 8-氯-N-[4-(三氟甲氧基)苯基]喹啉-2-胺或其药学上可接受的盐，抑制感染 HIV-1 的患者体内 HIV-1 的复制。
• Compounds and pharmaceutical compositions containing at least one of the compounds
  申请人：ABIVAX

  公开号：US11014918B2

  公开（公告）日：2021-05-25

  The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

  本公开一般涉及本文所述化合物的制造和使用，以预防、抑制或治疗癌症、艾滋病和/或早衰，或制造和使用药物组合物，其中包含至少一种化合物或其药学上可接受的盐，以及药学上可接受的载体，以预防、抑制或治疗癌症、艾滋病和/或早衰。